Author

C. D. Hillyer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. K. Debnath· 2 shared F. Curreli· 2 shared S. Ahmed· 2 shared A. Cho· 1 shared A. Drelich· 1 shared A. Gazumyan· 1 shared C. Gaebler· 1 shared C. Rice· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. K. Debnath

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of highly potent small molecule pan-coronavirus fusion inhibitors

F. Curreli, K. Chau, T.-T. Tran, I. Nicolau, S. Ahmed, P. Das, C. D. Hillyer, M. Premenko-Lanier, A. K. Debnath

This paper discovers and characterizes NBCoV63, a potent small molecule inhibitor effective against multiple SARS-CoV-2 variants and other coronaviruses.

bioRxiv · Jan 17, 2023Pharmacology & Toxicology

Stapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro

F. Curreli, S. M. B. Victor, S. Ahmed, A. Drelich, X. Tong, C.-T. K. Tseng, C. D. Hillyer, A. K. Debnath

This study designs stapled peptides based on the ACE2 helix to inhibit SARS-CoV-2 infection, showing potent antiviral activity with no cytotoxicity.

bioRxiv · Aug 25, 2020Pharmacology & Toxicology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology